United Therapeutics Corporation · NASDAQ:UTHR
United Therapeutics — J.P. Morgan Healthcare Conference 2026
14 slides from United Therapeutics's conference presentation, Jan 12, 2026
Slide 1: United Therapeutics Corporation
United Therapeutics Corporation J.P. Morgan Healthcare Conference JANUARY 12, 2026
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement All statements in this presentation are made as of January 12, 2026. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical
Slide 3: United Therapeutics: A Growth Story Unlike Any Other in Biotech
3 United Therapeutics: A Growth Story Unlike Any Other in Biotech UTHR: A Public Benefit Corporation
Slide 4: Double-Digit Compound Growth Expected to Continue into Next Decade
500 0 1,000 1,500 2,000 2,500 3,000 12 /31 /2 0 02 12 /31 /2 0 03 12 /31 /2 0 04 12 /31 /2 0 05 12 /31 /2 0 06 12 /31 /2 0 07 12 /31 /2 0 08 12 /31 /2 0 1. CAGR = Compound Annual Growth Rate 2. Since Remodulin approval in 2002 09 12 /31 /2 0 10 12 /31 /2 0 11 12 /31 /2 0 12 12 /31 /2 0 13 12 /31 /2
Slide 5: RemunityPro – State-of-the-Art PAH Delivery Devices
# 5 RemunityPro – State-of- the-Art PAH Delivery Devices UTHR: A Public Benefit Corporation
Slide 6: Advanced Therapeutics Addressing Rare Disease
6 Advanced Therapeutics Addressing Rare Disease
Slide 7: Tyvaso DPI is the Best Positioned Inhaled Prostacyclin
7 Tyvaso DPI is the Best Positioned Inhaled Prostacyclin DOSING TOLERABILITY PARTICLE DEPOSITION EASE OF USE UTHR: A Public Benefit Corporation
Slide 8: Tyvaso DPI: The first and only DPI device tailored for drug delivery to the distal lungs
8 Tyvaso DPI®: The first and only Low flow, High flow, DPI device like Tyvaso DPI device Drug Druglike other devices tailored for drug delivery to the distal lungs for PH1,2 Drug concentration 1. Colleen McEvoy, et al. Tyvaso DPI: Drug-device characteristics and patient clinical considerations, Pulm
Slide 9: TETON-2: Overwhelmingly Positive Phase 3 Results for Idiopathic Pulmonary Fibrosis
9 TETON-2: Overwhelmingly Positive Phase 3 Results for Idiopathic Pulmonary Fibrosis1,2 H-L3 estimate: 95.6mL (95% CI, 52.2, 139.0) P<0.0001 TETON-1 Data Expected Late 1Q/Early 2Q 2026 1. The use of Tyvaso (inhaled treprostinil) for IPF is an investigational use and has not been approved by the FDA.
Slide 10: Ralinepag: Potential First and Only Once-Daily Potent Prostacyclin Agonist
10 Ralinepag1: Potential First and Only Once-Daily Potent Prostacyclin Agonist 36.3m (p=0.004) mean 6MWD2 increase from OLE3 Baseline4 ADVANCE OUTCOMES Data Expected Late 1Q/Early 2Q 20265 1. Ralinepag is not approved for pulmonary arterial hypertension or any other indication. 2. 6MWD = six-minute
Slide 11: Three Platforms for Creating an Unlimited Supply of Transplantable Organs
11 Three Platforms for Creating an Unlimited Supply of Transplantable Organs Allogeneic Autologous Xenotransplantation Regenerative Medicine Regenerative Medicine UTHR: A Public Benefit Corporation
Slide 12: United Therapeutics: A Growth Story Unlike Any Other in Biotech
12 United Therapeutics: A Growth Story Unlike Any Other in Biotech PBC PHILOSOPHY When our patients succeed, we all succeed FINANCIAL FOUNDATION Unparalleled combination of commercial execution and strong cash flow STRATEGIC GROWTH PIPELINE Robust innovative pipeline with potential to deliver transf
Slide 13: Q&A
13 Q&A Dr. Martine Rothblatt Chairperson & Chief Executive Officer Michael Benkowitz FPO – clean up image President & Chief Operating Officer James Edgemond Chief Financial Officer & Treasurer
Slide 14: guna
guna United Therapeutics PUBLIC BENEFIT CORPORATION A ARTY a A
United Therapeutics — J.P. Morgan Healthcare Conference 2026 on 6ix